T. Rowe Price Investment Management, Inc. Nurix Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,473,956 shares of NRIX stock, worth $24.8 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,473,956
Previous 2,428,283
1.88%
Holding current value
$24.8 Million
Previous $28.8 Million
2.32%
% of portfolio
0.02%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding NRIX
# of Institutions
174Shares Held
79.4MCall Options Held
126KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$68.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$60.8 Million2.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.47MShares$44.7 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.95MShares$39.6 Million4.19% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$38.9 Million0.45% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $472M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...